1. IUPHAR-IUTOX Exchange Symposium (July 18, 2019; Honolulu)
Following the successful IUTOX symposium held at the WCP2018 congress in Kyoto it was IUPHAR’s turn to organise and hold a symposium at ICTXV2019 (co-hosted by SOT) at the Hawaii Convention Center. IUPHAR charged the Pharmacogenetics and Pharmacogenomics Section to organise the symposium which was done in collaboration with the Drug Metabolism and Drug Transport Section chaired by Prof Matthias Schwab. The title of the stand-alone symposium “Precision Medicine and ADME-Targets” and was chaired by Andrew Somogyi. Speakers and their presentation titles were:

Assoc Prof. Nuala Helsby (University of Auckland, New Zealand) “Pharmacogenomics of chemotherapy: personalizing old drugs”
Assistant Professor Bhagwat Prasad (University of Washington, USA) “New vistas in prediction of non-genetic variability in UGT2B17 for applications in precision medicine”.
Professor Andrew Somogyi (University of Adelaide, Australia) “Precision medicine for First Nations people: lessons from Aboriginal Australians”
Professor Deanna Kroetz (University of California San Francisco, USA) “Reverse Translational Studies to Identify Novel Mechanisms of Drug-Induced Toxicity”.

A more detailed report plus photographs has been provided to IUPHAR for inclusion in the next issue of Pharmacology International.

2. IUPHAR Support for symposium at 15th European ISSX (International Society for the Study of Xenobiotics) - 14th EACPT (European Association for Clinical Pharmacology and Therapeutics) Meeting in Geneva (June 7-10, 2020). This is being co-ordinated by Prof Ann Daly (Vice Chair Pharmacogenetics and Pharmacogenomics Section). The title of the symposium is “Implementation of Pharmacogenomic testing” and is a joint symposium with IUPHAR which is providing travel support for the speaker from Africa.

3. The Section is considering a joint symposium at the Asia-Pacific ISSX meeting in Bangalore for 2021.

4. Discussion will be underway very shortly as to how the Section can provide strong support and be involved in international studies addressing Serious Adverse Drug Reactions which to date have been very much at a national level, when what is desperately needed is at an international level including contributions from developed, developing and underdeveloped nations from all continents (except Antarctica).